MedTrace Logo

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

NCT04342910 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2026-01-20

No results posted yet for this study

Summary

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.

Conditions

Interventions

DRUG

camrelizumab

200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.

DRUG

Apatinib Mesylate

250 mg qd

DRUG

Paclitaxel

80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

DRUG

Irinotecan

180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianming Xu, Ph.D · Affiliated Hospital, Academy of Military Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2026-04-01
Completion
2026-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342910 on ClinicalTrials.gov